How to access Xadago from Oman, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Omanian patient with Parkinson's disease experiencing OFF-episodes on levodopa/carbidopa may receive a prescription for Xadago (safinamide) from their treating neurologist or movement-disorder specialist. Xadago is FDA-approved as adjunctive therapy for Parkinson's OFF-episodes and developed by Zambon (with US rights held through licensing). It is not a controlled substance. In Oman, Xadago is not routinely registered for outpatient dispensing, so access is typically coordinated through the named-patient import pathway.
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Xadago is a once-daily oral monoamine oxidase-B (MAO-B) inhibitor with additional glutamate-modulating activity, taken at 50 mg or 100 mg. Eligibility anchors to established Parkinson's disease, optimised levodopa/carbidopa regimen, and persistent OFF-episodes. Your neurologist will characterise OFF-time, confirm optimal levodopa dose, screen for dyskinesia tolerance, and review concomitant medicines to avoid serotonin-syndrome risk from concurrent MAO inhibitor combinations.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Xadago legally importable into Oman?
Yes, through the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) named-patient / special-access import framework. The mechanism permits an Omanian-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating neurologist. Parkinson's diagnosis, levodopa regimen optimisation, OFF-episode diary.
- Baseline assessment. Motor fluctuations, dyskinesia tolerance, concomitant-medication review for serotonergic and MAO-interaction risk, hepatic/ophthalmologic baseline per labeling considerations.
- DGPADC named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, and dosing plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Xadago from authorised distribution under DSCSA.
- Ambient shipment. Xadago ships under controlled ambient conditions with chain-of-custody documentation.
- Arrival and dispensing. The hospital pharmacy releases the bottle with titration and concomitant-medicine guidance.
What documentation your physician needs
- Clinical rationale letter confirming Parkinson's with OFF-episodes and Xadago as the indicated adjunct
- Verification of Omanian medical license
- Levodopa/carbidopa regimen documentation
- OFF-episode diary evidence
- Concomitant-medication review
- Planned dosing schedule (typically 50 mg titrated to 100 mg)
Reserve Meds provides a physician documentation kit bundling templates DGPADC reviewers expect for Parkinson's adjunct named-patient imports.
Costs and timing
Xadago's US cash-pay drug-only reference cost sits in an indicative 2026 annual range of roughly USD 8,000-11,000 for continuous daily dosing. International logistics, DGPADC documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.
Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete DGPADC application is submitted.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Mechanism, approval status, and treatment course
Xadago (safinamide) is a selective and reversible monoamine oxidase-B (MAO-B) inhibitor with additional state-dependent sodium-channel blockade and modulation of stimulated glutamate release. FDA approval: 2017. EMA approval: 2015. The labelled indication is the adjunctive treatment of Parkinson's disease in patients on a stable dose of levodopa/carbidopa experiencing OFF-episodes. Xadago is supplied through the US specialty distribution channel only; Reserve Meds sources from a US-licensed authorised wholesaler under Drug Supply Chain Security Act (DSCSA) chain-of-custody and ships under the documentation framework DGPADC reviewers expect.
Dosing. Oral 50 mg once daily for two weeks, then 100 mg once daily as tolerated. No required food restriction. Hepatic-impairment dose caps apply (max 50 mg in moderate impairment; contraindicated in severe). The Omani treating physician documents the planned dose, the titration interval, and the response endpoint in the DGPADC application package.
Tertiary referral landscape in Oman
Xadago cases in Oman are most commonly initiated and followed at tertiary referral centres with subspecialty expertise in the indication. These include Sultan Qaboos University Hospital, Royal Hospital Muscat, and Khoula Hospital. The treating physician of record (the Omani-licensed neurologist, haematologist, or relevant subspecialist) holds clinical responsibility for the case; Reserve Meds does not interpose between the patient and the prescriber. DGPADC pathway submissions are filed by the treating physician or the hospital pharmacy department, and Reserve Meds supplies the regulatory documentation package that DGPADC reviewers expect.
Where the patient is followed at a non-tertiary clinic, the patient is typically referred for the Xadago initiation visit to one of the centres above and then returns to local follow-up with monthly or quarterly tertiary review, depending on the clinical picture. Reserve Meds coordinates the refill cadence so that the next shipment is in country at least 7 days before the patient's current supply ends.
Monitoring and continuity of care
The Omani treating physician follows a standard monitoring schedule once Xadago is initiated:
- Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II and III at baseline, 8 weeks, then quarterly
- Patient OFF-time diary (Hauser diary or equivalent) at baseline and 8 weeks to quantify treatment response
- Annual dilated fundus examination given the theoretical retinal-degeneration signal observed in long-term rat toxicology
Reserve Meds is not involved in the clinical monitoring itself, but supplies refill cadence reminders to the patient and the treating physician so that the next-month supply is delivered in advance of the patient's next scheduled clinic visit. The first refill is shipped at week 3 of the initial cycle so that any titration adjustment from the 4-week visit can be reflected in the dose supplied for cycle 2.
Concomitant medications and safety considerations
Before Xadago is initiated, the Omani treating physician reconciles every concomitant prescription, over-the-counter, and herbal medicine the patient is taking. Key safety points the physician documents in the DGPADC package:
- Avoid concurrent use with other MAO inhibitors, meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John's wort, cyclobenzaprine, and most antidepressants because of serotonin-syndrome and hypertensive-crisis risk; the prescribing neurologist will reconcile every concomitant medicine before initiation
- Tyramine-rich-food caution is not required at 100 mg/day given MAO-B selectivity is preserved at therapeutic doses, but the patient is counselled to report severe headache or chest pain immediately
- Common adverse effects include dyskinesia worsening (titrate levodopa down if intolerable), insomnia, nausea, and orthostatic light-headedness; rare but serious effects include impulse-control disorders and falls
The patient is given a written counselling document in the language of care identifying which symptoms warrant immediate clinical contact and which can wait for the next scheduled visit. Reserve Meds supplies a generic counselling-document template that the treating physician adapts to the patient's case.
Funding considerations in Oman
Xadago is supplied on a cash-pay basis. Some Omani private medical insurers consider named-patient imports of FDA-labelled medicines on a case-by-case basis, particularly when the insurer's medical director can review the clinical rationale letter and the DGPADC authorisation. Reserve Meds supplies the documentation package the insurer requires for review but does not adjudicate or process claims directly.
For self-pay patients, Reserve Meds issues a transparent quote at intake covering the drug-only band, international logistics, DGPADC documentation handling, and concierge case coordination. The quote is fixed for the duration of the initial 90-day cycle and re-issued for each subsequent cycle if the dose changes. Patients are encouraged to ask their Omani treating physician about manufacturer patient-assistance pathways where available, although most US manufacturer assistance programs are restricted to US residents.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and DGPADC review.
- Logistics. Ambient-controlled shipment to your prescribing hospital.
- Concierge case lead. A named point of contact coordinating monthly refills.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in Oman? Yes, when executed through the DGPADC named-patient framework with appropriate documentation. See our trust and compliance page.
Is Xadago a controlled substance? No. Safinamide is not a scheduled controlled substance.
How does Xadago compare with rasagiline or selegiline? All three are MAO-B inhibitors; Xadago adds glutamate-modulating activity. Your neurologist selects based on the clinical picture, concomitant medicines, and tolerability.
What are the key drug interactions? Concurrent use with other MAO inhibitors, opioid analgesics such as meperidine, and certain serotonergic agents is contraindicated. Your neurologist will review your full medication list at initiation.
Will insurance cover this? Cash-pay is the default. Some Omanian private insurers consider case by case; we supply documentation but do not process claims directly.
How long does the patient typically remain on Xadago? Xadago is a chronic adjunctive therapy. The neurologist re-evaluates response at 8 weeks and quarterly thereafter. Most responders remain on therapy for years; non-responders are discontinued and switched within the MAO-B or adjunct class.
Can the patient travel internationally while on Xadago? Yes. Xadago is not a controlled substance and travels in original labelled packaging with a copy of the prescription. The patient should carry a 30-day supply minimum on the person rather than checked luggage.
What happens if the patient misses a dose? Take the missed dose as soon as remembered the same day. If it is the next day, skip and resume the regular schedule. Do not double-dose. Three consecutive missed days reverts the patient to the 50 mg titration step.
Is generic safinamide available? As of 2026 there is no FDA-approved generic safinamide in the US distribution channel. Reserve Meds sources the Zambon/Supernus branded product only, with DSCSA chain-of-custody documentation throughout.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.